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The incidence of hepatitis C virus (HCV) infections among human immunodeﬁciency virus (HIV)-infected men who have sex
with men has increased in recent years and is associated with high-risk sexual behavior. Behavioral interventions that target high-
risk behavior associated with HCV transmission and treatment with direct-acting antivirals may prevent further HCV infections.
We predicted the effect of behavioral and treatment interventions on HCV incidence and prevalence among HIV-infected men
who have sex with men up to 2030 using a HCV transmission model parameterized with data from the Swiss HIV Cohort Study.
We assessed behavioral interventions associated with further increase, stabilization, and decrease in the size of the population with
high-risk behavior. Treatment interventions included increase in treatment uptake and use of direct-acting antivirals. If we assumed
that without behavioral interventions high-risk behavior spread further according to the trends observed over the last decade and
that the treatment practice did not change, HCV incidence converged to 10.7/100 person-years. All assessed behavioral interven-
tions alone resulted in reduced HCV transmissions. Stabilization of high-risk behavior combined with increased treatment uptake
and the use of direct-acting antivirals reduced incidence by 77% (from 2.2 in 2015 to 0.5/100 person-years) and prevalence by 81%
(from 4.8% in 2015 to 0.9%) over the next 15 years. Increasing treatment uptake was more effective than increasing treatment efﬁca-
cy to reduce HCV incidence and prevalence. A decrease in high-risk behavior led to a rapid decline in HCV incidence, independent
of treatment interventions. Conclusion: Treatment interventions to curb the HCV epidemic among HIV-infected men who have sex
with men are effective if high-risk behavior does not increase as it has during the last decade; reducing high-risk behavior associated
with HCV transmission would be the most effective intervention for controlling the HCV epidemic, even if this was not accompa-
nied by an increase in treatment uptake or efﬁcacy. (HEPATOLOGY 2016;64:1856-1869).
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The hepatitis C virus (HCV) epidemic inhuman immunodeﬁciency virus (HIV)-infected patients has evolved quickly over the
past few years.(1-4) In Western countries, HCV is
increasingly transmitted among HIV-infected men
who have sex with men (MSM).(1,5-9) We observed, in
the Swiss HIV Cohort Study (SHCS),(10) a steep rise
in incidence of HCV infections among MSM without
history of injection drug use. In contrast, HCV inci-
dence stabilized among heterosexuals and decreased
among people who inject drugs.(3)
An international network of HCV transmission
among HIV-infected MSM was revealed by a phylo-
genetic study.(11) In this population, transmission is
associated with high-risk behavior including condom-
less traumatic anal intercourse, ﬁsting, use of recrea-
tional drugs, and group sex.(1,3,7,12,13) In the SHCS,
the increase in HCV incidence coincided with reduced
self-reported condom use among MSM on antiretrovi-
ral therapy (ART).(14)
Effective interventions to curb the HCV epidemic
among HIV-infected MSM remain to be estab-
lished. Behavioral interventions that target high-risk
sexual practices associated with HCV transmission
may prevent new HCV infections. Because recently
introduced treatments for HCV with second-
generation direct-acting antiviral agents (DAAs)
rapidly reduce HCV viral load and achieve high cure
rates, they offer an unprecedented opportunity to
prevent transmissions.
In this study, we analyzed data from the SHCS to
develop a mathematical model of HCV transmission
among MSM who do not inject drugs. We used the
model to replicate the HCV epidemic in Switzerland
and to estimate the effect of behavioral and treatment
interventions on HCV incidence and prevalence up to
2030.
Subjects and Methods
THE SWISS HIV COHORT STUDY
The SHCS is a nationwide, prospective cohort that
enrolls HIV-infected patients, aged 16 or above, since
1988, drawing from Swiss university hospitals, cantonal
reference hospitals, and private practices.(10,15) Written
informed consent is mandatory for inclusion in the
SHCS, and the study has been approved by all local
ethics committees. The SHCS includes 73% of HIV-
infected patients declared to the Swiss public health
authorities.(16) Clinical, behavioral, and laboratory data
are collected at enrollment and at follow-up visits every
6 months. The collected data include information on
antiretroviral and HCV treatments, sexual preferences,
condom use, and sex with stable and occasional part-
ners.(15) HCV-seronegative patients were screened bian-
nually for HCV infection between 1998 and 2006 and
yearly thereafter. Immunoblotting conﬁrmed positive
results by third-generation enzyme-linked immunosor-
bent assay. We included all HCV-seronegative MSM
who had at least one follow-up HCV antibody measure-
ment after January 2000. Patients with a positive HCV
serology at entry, those who seroconverted before 2000,
and those who reported injecting drug use during the
follow-up period were excluded from the incidence anal-
ysis. For the estimation of the incidence that we used to
ﬁt the model, the follow-up period ended at the ﬁrst
positive HCV serology or the last negative serology as
described previously.(3) For the analyses on sexual behav-
ior, the follow-up period ended at dropout or death.
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HCV TRANSMISSION MODEL
We adopted a system of ordinary differential equa-
tions to model HCV transmission among HIV-infected
MSM (Supporting Information). We set out to repro-
duce HCV incidence among HIV-infected MSM in
Switzerland between 2000 and 2013 by classifying the
population into compartments distributed by stage of
infection, risk groups and enrollment in care. Risk
groups included (1) individuals who do not engage in
sexual practices associated with HCV transmission
(group without high-risk behavior) and (2) individuals
who do engage in sexual practices associated with HCV
transmission (group with high-risk behavior). Each risk
group includes ﬁve compartments: (1) two HCV-
uninfected (susceptible) “in” and “out” of HIV care
(referred to as “in care” and “out of care” from now on);
(2) two HCV-infected in and out of care; and (3) one on
treatment for HCV only accessible for individuals in
care. The model structure is summarized in Fig. 1. Out
of care individuals can enter the in care category at a rate
x(t). Newly HIV-infected MSM enter the out of care
                                                                                                                                      
FIG. 1. Model structure. Individuals
are distributed in groups according to
their risk behavior (without and with
high-risk) and enrollment in HIV care.
Individuals switch from the group
without high-risk to the group with
high-risk at rate /r(t) and from the
group out of care to the group in HIV
care at rate x(t). Susceptible individu-
als may be infected by an external force
of infection (k) that accounts for infec-
tions not acquired by contacts within
the modeled population. Individuals
within the high-risk group may also
infect each other at an infection rate b.
Individuals with spontaneous HCV
clearance remain susceptible. Infected
individuals without spontaneous clear-
ance start HCV treatment at rate c(t).
Treatment lasts on average 1/g and
results in HCV clearance for a propor-
tion a of all treated patients. Individu-
als exit the system at rate l from
all compartments. Abbreviations: I,
infected; i, in care; o, out of care; S,
susceptible; T, on treatment.
                                                                                                                                      
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susceptible category at a rate that varies over time q(t). A
fraction /w(t) of these individuals enter the susceptible
compartment in the high-risk group, where w(t) is the
proportion of newly HIV-infected MSM who have
unprotected sex with occasional partners, which we term
unsafe sex; and / is the proportion of these individuals
who also engage in high-risk behavior and therefore are
at risk of HCV transmission. High-risk behavior com-
prises condomless traumatic anal intercourse, ﬁsting, use
of recreational drugs, and group sex. / is referred to as
the high-risk/unsafe sex ratio. The remaining newly
HIV-infected MSM enter the susceptible compartment
in the group without high-risk. Individuals switch from
the group without high-risk to the high-risk group at a
rate /r(t), where r(t) is the rate at which individuals
start to have unsafe sex. We refer to w(t) and r(t) as
high-risk recruitment parameters. All susceptible individu-
als may be infected by an external force of infection k
that accounts for infections unrelated to high-risk con-
tacts within the modeled population. Because k affects
all individuals, incidence is always k irrespective of
interventions. Individuals within the high-risk group
infect each other at an infection rate b. This rate is asso-
ciated with the probability of establishing an infection
given an infectious contact. Infected individuals in both
risk groups start treatment at a rate c(t). The mean dura-
tion of treatment is 1/g and results in HCV clearance for
a fraction a of treated individuals. Individuals who clear
the infection are again susceptible. Individuals exit the
system at a rate l from all compartments, which indi-
cates the end of their sexual activity in Switzerland. We
accounted for reinfections and naive infections by split-
ting this model. The resulting model (“reinfection mod-
el”) is equivalent to the main one, and its structure is
displayed in Supporting Fig. S1.
MODEL PARAMETERIZATION
Most parameters were measured from SHCS data.
The high-risk/unsafe sex ratio (/), the proportion of
individuals out of care, and the change in diagnosis
rate over calendar year were estimated from published
data; the infection rate b and the assortativity coefﬁ-
cient were ﬁtted to the incidence data by maximum
likelihood (Supporting Information).
We obtained the numbers of newly susceptible indi-
viduals q(t) from the SHCS database and the propor-
tion of HIV-infected MSM out of the SHCS. These
numbers were based on new registrations into the
cohort. We used Bayesian Poisson regression mod-
els(17,18) to estimate entrance rates from these numbers.
HCV treatment rates were determined separately for
the periods 2000-2005 and 2006-2013 because treat-
ment uptake substantially increased between those
periods in the SHCS.(19) We modeled this transition
as a logistic function (Supporting Information). Initial
conditions were also approximated from data, namely,
the numbers of patients susceptible, infected, and on
treatment for HCV at the beginning of 2000. We used
SHCS information on self-reported unprotected sex
with occasional partners to estimate two time-
dependent high-risk recruitment parameters: (1) the pro-
portion of patients who reported unsafe sex w(t) during
their second follow-up visit, which we consider to
reﬂect their sexual behavior following HIV diagnosis,
and (2) the rate r(t) at which patients without unsafe
sex at the beginning of the follow-up started to engage
in this practice.
We estimated the fraction of patients out of care by
combining data from the European Men-Who-Have-
Sex-With-Men Internet survey(20) and a modeling
study on HIV transmission among MSM in Switzer-
land.(21) We found transition rates from HIV infection
to enrollment in care that led the model to reproduce
this fraction by assuming that the rates reﬂected the
increase estimated by van Sighem et al.(21)
Uncertainty analyses were based on Latin hypercube
sampling. We sampled the infection rate b, the exit
rate l, and the external force of infection k to produce
combinations of parameters using this technique. We
then obtained model solutions for each combination to
determine 95% conﬁdence intervals (CIs) (Supporting
Information).
INTERVENTIONS TO REDUCE
HIGH-RISK BEHAVIOR AND
TREATMENT SCENARIOS
We projected future HCV incidence based on hypo-
thetical interventions that reduce high-risk behavior and
increase treatment uptake and/or efﬁcacy. Projections of
the high-risk recruitment parameters were based on
observed trends. Behavioral interventions included three
scenarios. (1) Pessimistic scenario: no intervention, in
which the size of the high-risk group grows further
according to the trend observed in the SHCS over the
last decade. In this scenario an increasing number of
patients enter the high-risk group, until high-risk
recruitment parameters duplicate the last observation;
thereafter, they saturate. (2) Intermediate scenario: health
promotion or autonomous saturation leading to a stable
size of the high-risk group. (3) Optimistic scenario:
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health promotion or autonomous saturation leading to a
decreasing size of the high-risk group. In this scenario,
no more patients enter the high-risk category. Treat-
ment interventions included use of DAAs and increased
treatment uptake. We considered two scenarios for
treatment uptake, according to treatment rate: (1)
remained constant at the observed average between
2006 and 2013 (22% per year) and (2) increased to 100%
per year; i.e., the average time from infection to treatment
was reduced to 1 year. Our model also compared the
impact of DAAs(22,23) with interferon-based treat-
ments.(24) The average duration of interferon-based treat-
ment was assumed to be 9 months and to result in 53%
sustained virologic response, as observed in the
SHCS.(19) Treatment with DAAs was assumed to last 3
months on average and to result in 90% sustained viro-
logic response, independent of HCV genotype.(22,23) We
reported predicted incidence and prevalence curves by
combining these scenarios.
In a further analysis, we assessed a best-case scenario of
risk behavior. In this analysis we accelerated the decrease
in the size of the high-risk group associated with the opti-
mistic scenario. We assumed that individuals in the high-
risk group transit to the group without high-risk at a rate
that equals the last observed rate of transition from the
group without to the group with high-risk behavior. This
approximation aims to reﬂect the speed of behavioral
change observed in the population.
SENSITIVITY ANALYSIS I:
DIFFERENT HIGH-RISK/UNSAFE
SEX RATIOS
The approximated value for the high-risk/unsafe sex
ratio that we used in the main analyses (0.25 as observed
in Schmidt et al.(13)) may not accurately reﬂect the reali-
ty as it does not include all sexual practices leading to
HCV transmission. We therefore performed model ﬁts
and projections for all scenarios, where this ratio
increased in steps of 0.05 from 0.2 to 0.4.
SENSITIVITY ANALYSIS II:
IMPORTED INFECTIONS
In this analysis we assumed that an increasing per-
centage of incident HCV infections observed in the
high-risk group were not acquired by contact with oth-
er HIV-infected MSM in Switzerland (imported
infections). We performed model ﬁts and projections
for all scenarios, where the percentage of imported
infections increased from 3% to 27%. These values
were achieved by assuming increasing external forces of
infections k in the high-risk group.
SENSITIVITY ANALYSIS III:
PROTECTIVE EFFECT OF
PREVIOUSLY CLEARED HCV
INFECTION
Some studies suggest that the risk of reinfection
after clearance may be lower than the risk of infection
in naive individuals.(25) We assessed the effect of this
potential protective effect by assuming that the proba-
bility of HCV transmission given an infectious contact
is lower in individuals who have cleared HCV than in
naive individuals. We performed model ﬁts and projec-
tions for all scenarios, where the probability of reinfec-
tion was reduced by 13%, 25% (as in Martin et al.(26)),
and 50%.
All procedures, including calibration, ﬁtting
algorithms, and uncertainty analyses, were imple-
mented in R.(27) Differential equations were solved
with the R package deSolve.(28,29)
TABLE 1. Characteristics of All MSM Registered in the
SHCS Who Were Included in the Parameterization of the
Model
Total number of patients 5,052
Age at registration (median [IQR]) 37 (31-44)
Follow up time (years, median [IQR]) 7.8 (3.6-14.9)
ART
Yes 4,619 (91.4%)
No 433 (8.6%)
CD4 cell count at ART start (cells/lL, median [IQR]) 268 (156-389)
Viral load at ART start (log10 copies/mL, median [IQR]) 4.8 (4.2-5.3)
Intravenous drug use* 127 (2.5%)
Information on sexual partners
Sex with stable partners (n [%])
Yes 3,655 (72.3%)
No 1,257 (24.9%)
Refuse to answer 91 (1.80%)
Missing 49 (0.97%)
Condom use with stable partner (n [%])
Inconsistent or never† 2,080 (56.9%)
Refuse to answer 29 (0.8%)
Missing 1 (0%)
Sex with occasional partners (n [%])
Yes 3,860 (76.4%)
No 975 (19.3%)
Refuse to answer 168 (3.3%)
Missing 49 (1.0%)
Condom use with occasional partner (n [%])
Inconsistent or never† 1,860 (48.1%)
Refuse to answer 40 (1.0%)
Missing 2 (0.0%)
*Out of all MSM. These patients were excluded from the
analyses.
†Ever reported.
Only patients with available questionnaires on sexual partners
who were followed beyond 2000 were included.
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Results
STUDY POPULATION
A total of 5,052 MSM were included in the analy-
ses (Table 1). Median age at registration in the
SHCS was 37 years (interquartile range [IQR] 31-
44). Ninety-one percent of all patients started ART
during the follow-up time. Sex with occasional
partners was reported by 3,860 (76%) MSM, of
whom 1,860 (48%) also reported inconsistent con-
dom use.
MODEL PARAMETER ESTIMATES
Model parameters used to reproduce observed
HCV incidence in the SHCS are shown in Table 2.
An average of 190 HCV-negative MSM newly diag-
nosed with HIV and without history of intravenous
drug use were enrolled into the cohort per year (Sup-
porting Fig. S2A). The proportion of patients who
reported unsafe sex during their second follow-up vis-
it was 5% in 2000 and increased continuously to reach
13% in 2013 (Fig. 2A). The transition rate to unsafe
sex rose from 0.04 per year in 2000 to 0.13 per year in
2012 (Fig. 2B). We assumed that a fraction (0.25) of
patients who engage in unsafe sex also engage in
high-risk behavior. This approximation reﬂects the
ratio between the number of patients who reported
frequent bondage, dominance/submission, sadism/
masochism, or ﬁsting and those who reported unpro-
tected anal intercourse with nonsteady partners in
Schmidt et al.(13) The percentage of patients treated
for HCV was 11% before 2006 and rose to 42%
TABLE 2. Model Parameters Used to Reproduce the Incidence Observed Between 2000 and 2013
Parameter Definition Value Functional form Source
x(t) Rate of enrollment in care
(from HIV infection, per year)
0.45 before 2005
0.58 after 2005
Estimation using
data from
van Sighem
et al.(21)
q(t) New HCV-uninfected MSM rate*,†
(individuals per year/0.8)
(135-257) Splines smoothing of a seriesof yearly rates SHCS
w(t) Proportion of individuals
with unsafe sex at entry‡
3:2 3 1022 if t  3:8
6:1 3 102221:6 3 1022 t 12:5 3 1023 t2
2 7:2 3 1025 t3 if 3:8 < t < 13:5
SHCS
/ High-risk/unsafe sex ratio§ 0.25 (13)
r(t) Rate at which individuals start
to have unsafe sex (per year)‡
4:1 3 10221 2 3 1023ðt 1 1:5Þ 2 1:4 3 1023
ðt 1 1:5Þ21 1:2 3 1024ðt 1 1:5Þ3
SHCS
b Infection rate (95% CI, per year) 5.1 (4.3-5.7) Fit
a Proportion of patients who clear
infection after treatmentk
0.53 SHCS
(19)
g 1/average treatment
duration (per year)
4/3 SHCS
k External force of
infection 3 10-3 (per year)¶
2.3 SHCS
l Exit rate (95% CI) 0.049 (0.045-0.053) SHCS
c(t), c0(t) Rate of treatment for each risk
group (per year)
(0.02-0.22) 0.2/(1 1 e-t12006) 1 0.02 SHCS
S2000 1 S
0
2000 Initial number uninfected patients
†,# 1,552 SHCS
I2000 Initial number of infected patients
†,# 8 SHCS
T2000 Initial number of patients
on treatment†,#
0 SHCS
*Rates were obtained applying Bayesian Poisson regression models with nonparametric smoothing priors using the R package
INLA.(17)
†Scaled to the HIV-infected MSM population in Switzerland assuming that 80% of all individuals in this population enroll in the
SHCS.
‡The origin is 2000.
§Ratio between the number of patients who reported frequent bondage, dominance/submission, sadism/masochism, or ﬁsting and
those who reported unprotected anal intercourse with nonsteady partners. The approximated ratio between patients who reported skin
damage with bleeding and those who reported unprotected anal intercourse with nonsteady partners is 0.23.
kWeighted average according to time from diagnosis to treatment initiation.
¶1999-2000 average incidence rate.
#Initial value in year 2000.
Abbreviations: I, infected; S, susceptible; T, on treatment.
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between 2006 and 2013. Consistently, when we com-
pared the periods 2000-2005 and 2006-2013, the
average treatment rate increased by a factor of 10: 2%
per year in the earlier period versus 22% per year in
the later period (Table 2). The exit rate estimated
from patients who died or left Switzerland, as speci-
ﬁed in the cohort, was 0.049 (95% CI 0.045-0.053),
which implies an average time of over 20 years of sex-
ual activity. We estimated that on average 84% of
HIV-infected MSM were in care between 2000 and
2010. Associated rates of enrollment in care were
found to be 0.45/year and 0.58/year before and after
2005 respectively. These rates imply times from HIV
infection to enrollment in care of 2.2 and 1.73 years,
respectively. Supporting Fig. S3 shows the likelihood
curve for the estimated rate of infection.
OBSERVED AND MODELED HCV
INCIDENCE, 2000-2013
Modeled HCV incidence accurately reproduces
observed HCV incidence (Fig. 2C). It increased from
0.2/100 person-years (py) in 2000 to 1.0/100 py in
2013.
IMPACT OF INTERVENTIONS TO
REDUCE HIGH-RISK SEXUAL
BEHAVIOR AND TREATMENT
SCENARIOS, 2015-2030
Pessimistic Scenario: Growing Size of
the High-Risk Group
If the spread of high-risk practices associated with
HCV transmission was unchecked, the model pre-
dicted a steep increase in HCV incidence and preva-
lence. Incidence converged to 10.7/100 py if
treatment practice remained unchanged (upper panel,
Fig. 3A). If treatment uptake increased considerably,
incidence continued to rise at a lower rate than with
the current treatment practice, to reach 10.4/100 py
and 8.5/100 py in 2030 with and without DAAs,
respectively (upper panel, Fig. 3A). Interestingly, the
highest predicted incidence was observed in the
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FIG. 2. High-risk recruitment parame-
ters and HCV incidence. (A) Propor-
tion of new individuals who have
unprotected sex with occasional partners
(unsafe sex). (B) Rate at which individ-
uals start to have unsafe sex. (black
stars, observed; continuous black line,
functional ﬁt). The model assumed that
a fraction of the patients with unsafe
sex also engage in high-risk behavior,
which can result in HCV transmission.
(C) HCV incidence rates observed in
the SHCS (green dots and error bars)
and obtained with the transmission
model (continuous blue line; shaded,
95% CIs).
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scenario with current treatment uptake and DAAs. A
combination of two factors explains this behavior:
ﬁrstly, short-duration effective treatments led to rap-
idly cured infections, which in turn resulted in an
enlarged size of the susceptible group; and secondly,
the treatment rate was not large enough to contain
transmission. This outcome was observed in all
scenarios.
Prevalence also increased rapidly in this scenario.
Without change in treatment uptake, it was above 36%
in 2030 irrespective of the type of treatment. But if
treatment uptake increased considerably, prevalence in
2030 was 23.1% and 11% without and with DAAs,
respectively (lower panel, Fig. 3A). The model also
predicted that in 2030 reinfection will account for at
least 44% of all incident infections (versus 3.6% in
2015; Supporting Table S1)
Intermediate Scenario: Stable Size of
the High-Risk Group
Stabilization of high-risk behavior without change
in treatment uptake led to a rapidly saturated incidence
at around 2.6/100 py if treatment uptake did not
change. If treatment uptake increased considerably,
DAAs led to a continuous decline in incidence, reach-
ing 0.5/100 py in 2030 (upper panel, Fig. 3B). The
beneﬁt of DAAs compared to interferon-based therapy
was largest in this case. Prevalence displayed a similar
pattern. It stabilized at around 12.7% if treatment
                                                                                                                                      
FIG. 3. Projected HCV incidence and prevalence in HIV-infected MSM assuming that the size of the high-risk group grows (A),
and health promotion or autonomous saturation leading to (1) stable size of the high-risk group (B) and (2) decreasing size of the
high-risk group (C). Two scenarios of future treatment uptake were included: (1) treatment rate constant at the average between 2006
and 2013 (22% per year, continuous lines) and (2) increased treatment rate (100% per year, dashed lines). Two treatment alternatives
are displayed: second-generation DAA regimens (red) and interferon-based regimens (blue). Dashed, gray, vertical lines indicate the
beginning of the projection period.
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uptake did not change and decreased considerably to
reach 0.9% at the highest treatment uptake with
DAAs (lower panel, Fig. 3B). The model also pre-
dicted that in 2030 reinfection will account for at least
23% of all incident infections (Supporting Table S1).
Optimistic Scenario: Decreasing Size of
the High-Risk Group
A reduction in the frequency of high-risk practices
associated with HCV transmission led to an immedi-
ate decrease in incidence, regardless of treatment
uptake and type of treatment (upper panel, Fig. 3C).
In this scenario, introducing DAAs had only a modest
inﬂuence on incidence and prevalence. As expected,
the minimal incidence and prevalence predicted in this
study were achieved in this scenario when DAAs were
introduced at the highest treatment uptake (incidence
0.2/100 py, prevalence 0.4% in 2030; lower panel,
Fig. 3C). The model predicted that in 2030 reinfection
will account for at least 7.6% of all incident infections
(Supporting Table S1).
Best-Case Scenario: Rapidly Decreasing
Size of the High-Risk Group
In this scenario, the model predicted an immediate
steep decline in HCV incidence (upper panel, Fig. 4A).
In 2025 incidence saturated at 0.2/100 py irrespective of
treatment interventions. Prevalence also declined con-
siderably in this scenario. It ranged between 2.5% and
0.4% in 2030 (lower panel, Fig. 4A).
Figure 4B shows HCV incidence and prevalence
associated with different scenarios of high-risk behav-
ior when assuming treatment with DAAs and current
treatment rate.
In all scenarios, incidence was more sensitive to the
considered changes in treatment uptake than to
changes in treatment efﬁcacy (Fig. 3). Trends for
high-risk recruitment parameters in the ﬁrst
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FIG. 4. (A) Projected HCV incidence (upper panel) and prevalence (lower panel) in HIV-infected MSM assuming that no additional individ-
uals enter the high-risk group and that individuals in the high-risk group transit to the group without high-risk at a rate that equals the last
observed rate of transition from the group without high-risk behavior to the group with high-risk behavior. Two scenarios of future treatment
uptake were included: (1) treatment rate constant at the average between 2006 and 2013 (22% per year, continuous lines) and (2) increased treat-
ment rate (100% per year, dashed lines). Two treatment alternatives are displayed: second-generation DAA regimens (red) and interferon-based
regimens (blue). Dashed, gray, vertical lines indicate the beginning of the projection period. (B) Effect of reductions in high-risk behavior when
assuming treatment with DAAs and current treatment rate.
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two behavioral scenarios are displayed in Supporting
Fig. S4. Supporting Table S2 shows changes in high-
risk behavior associated with each scenario.
SENSITIVITY ANALYSIS I:
DIFFERENT HIGH-RISK/UNSAFE
SEX RATIOS
Projected HCV incidence with all interventions
assuming increasing high-risk/unsafe sex ratios (i.e.,
increasing the proportion of patients with unsafe sex
who also engage in high-risk behavior) are shown in
Supporting Fig. S5. In the pessimistic case scenario of
risk behavior, the model predicted higher incidence and
prevalence with increasing high-risk/unsafe sex ratios.
Incidence in 2030 ranged from 8.2/100 py to 20.5/100
py and prevalence from 10.6% to 51.2%, with ratios of
0.2 and 0.4, respectively (left panels, Supporting Fig.
S5). Consistently, in the intermediate and optimistic
scenarios of risk behavior, predicted incidence stabilized
at higher values as high-risk/unsafe sex ratios increased
(center and right panels, Supporting Fig. S5). Despite
these differences, the effects of all interventions were
equivalent to those described in the main analysis.
SENSITIVITY ANALYSIS II:
IMPORTED INFECTIONS
Behavioral and treatment interventions were also
effective at decreasing HCV incidence and prevalence
when the proportion of infections assumed to be
imported increased. When this proportion was set to
be maximal (27%) in the intermediate scenario of risk
behavior, increased treatment uptake and efﬁcacy led
to incidence and prevalence reaching 0.7/100 py and
1.1% in 2030, respectively (Supporting Table S3). The
goodness of the ﬁt decreased as more infections
observed in the high-risk group were assumed to be
imported, suggesting a predominant role of domestic
transmission. Worsening ﬁts may lead to unrealistic
projections, especially in the pessimistic scenario
because the model becomes less capable of reproducing
the observed increase in incidence.
SENSITIVITY ANALYSIS III:
PROTECTIVE EFFECT OF
PREVIOUSLY CLEARED HCV
INFECTION
Predicted HCV incidence and prevalence decreased
as the reduction in reinfection probability increased
(Supporting Table S4). Incidence and prevalence dis-
played the same pattern observed in the main analysis
(Supporting Fig. S6). In the pessimistic scenario, with
a 25% reduction in reinfection probability, treatment
with DAAs at the highest treatment uptake led to 5.5/
100 py incidence (versus 8.5/100 py in the main analy-
sis) and 7.6% prevalence (versus 11.0% in the main
analysis). Despite these variations, the effect of all
interventions was equivalent to that described in the
main analysis, even when the protective effect was
strong.
Discussion
We reconstructed the HCV epidemic among HIV-
infected MSM in Switzerland between 2000 and 2013
using a mathematical transmission model based on
two risk groups. We used this model to predict the
future course of HCV incidence and prevalence in
HIV-infected MSM. Different modeled scenarios
based on hypothetical behavioral and treatment inter-
ventions showed that prevention of high-risk behavior
alone could result in considerably reduced HCV
transmission.
The model showed that substantially increasing
only treatment uptake would more effectively
reduce HCV incidence and prevalence than sub-
stantially increasing only treatment efﬁcacy. There
are fewer contraindications to DAAs-based treat-
ments than to interferon-based treatments, so
DAAs-based treatments may improve uptake. The
model predicts that if high-risk behavior continues
to increase according to the trends observed during
the last decade, HCV incidence will continue to
rise, despite increasing treatment uptake and efﬁca-
cy. However, stabilization of high-risk behavior
combined with a considerable increase in treatment
uptake and efﬁcacy could effectively reduce HCV
incidence and prevalence. Moreover, the beneﬁt of
DAAs over interferon-based therapy was highest in
this stable scenario when assuming high treatment
uptake. Reduction in high-risk behavior could lead
to a rapid decline in incidence within the next few
years, independently of improved treatment uptake
or efﬁcacy. The model predicted that reinfections
will account for an increasing proportion of all inci-
dent infections in the future. This is in line with
recent studies that have reported high rates of
reinfection.(30,31)
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STRENGTHS AND LIMITATIONS
A major strength of our analysis is that we estimated
most model parameters directly by using patient-level
data from the SHCS.(10,15) Most parameters corre-
sponded to a single population, so they were internally
consistent. The inclusion of data on the evolution of
sexual behavior among HIV-infected MSM over the
last decade was an additional strength of our model.
These data reveal heterogeneity,(32) which we captured
by splitting the population into two risk behavior
groups.
Due to the lack of data on speciﬁc high-risk practi-
ces, we had to assume that the proportion of people
with high-risk behavior was a constant fraction of the
population that engages in unsafe sex. We believe this
is a reasonable approximation to reality which allowed
us to take advantage of the available data on sexual
behavior. This quantity was based on published obser-
vations,(13) which may have led to an underestimation
of this fraction as it does not include all practices that
are believed to result in HCV transmission. However,
a sensitivity analysis which considered several values of
this parameter resulted in concordant predictions.
Another limitation was that we did not explicitly mod-
el the link between sexual behavior and recreational
intravenous drug use, which is increasingly recognized
as a risk factor for HCV transmission among
MSM(12,33) and may contribute to the HCV epidemic.
We did not include HIV-uninfected MSM in the
modeled population, but we think this was reasonable:
a recent Swiss survey showed that the prevalence of
HCV in HIV-uninfected MSM was only 0.4%, thus
not higher than that in the general population.(34) Our
approximation was based on the fact that there is no
evidence of boosted HCV transmission among HIV-
negative MSM. The reason HCV transmission seems
to be conﬁned to HIV-infected MSM is unknown.
Serosorting (the practice of using HIV status as a
decision-making point in choosing sexual partners) is
common but not generalized,(35) and its role in the
spread of HCV among HIV-infected MSM remains
uncertain. Further factors, including HIV-mediated
impairment of mucosal immunity, which is often not
completely restored during ART, may also play a role.
Importantly, the scale-up of HIV preexposure prophy-
laxis may reduce serosorting, which in turn could result
in an HCV transmission bridge from HIV-positive to
HIV-negative MSM.
Little is known about risk behavior patterns and
demographics of people with undiagnosed HIV
infections. However, 80% of HIV-infected MSM liv-
ing in Switzerland are estimated to be enrolled in the
SHCS.(16) Therefore, the data we used to parameterize
this model are likely to be representative of this
population.
The main model assumed a constant external force
of infection. Although the frequency of drug injection
among MSM in the SHCS was low (only 2.5% ever
reported) and stable over the study period (results not
shown), which supports our assumption, we undertook
a sensitivity analysis to evaluate the impact of increas-
ing the external force of infection in the high-risk
group. These increases are equivalent to more infec-
tions acquired by high-risk contacts outside the mod-
eled population (imported infections). The model
predictions suggested that behavioral and treatment
interventions can effectively reduce incidence and prev-
alence even when the number of imported infections is
large. Our conclusions also remained unchanged when
assuming that HCV clearance reduces the risk of sub-
sequent infections (protective effect). In this study, we
did not explore alternative explanations for increased
HCV transmissions over time, such as the emergence
of more transmissible HCV strains. However, previous
phylogenetic analyses revealed that many different
HCV strains were involved in its spread among HIV-
infected MSM,(11,36) so the emergence of a particularly
transmissible HCV strain is unlikely to be the main
driver of the epidemic. Finally, assuming that risk
behavior will continue to increase at the speed it has
over the last years (as we did in the pessimistic scenar-
io) may have led to unrealistically large sizes of the
population with high-risk behavior and resulted in a
very high prevalence for the pessimistic scenario. This
and the best-case scenario are extreme cases that bound
the possible future outcomes of the HCV epidemic.
Our results may not apply to populations of HIV-
infected MSM where HCV incidence has not
increased because these populations may not have the
same demographic, clinical, and behavioral characteris-
tics(37) as the population we studied. But HCV inci-
dence has recently increased among HIV-infected
MSM in many settings, as synthesized in a meta-
analysis.(9)
In this study, we did not use viral sequence data to
trace HCV transmissions. A recently published phylo-
genetic analysis in the SHCS(38) revealed that people
with closely related HIV viruses were more likely to
acquire HCV infection if their phylogenetic neighbors
were HCV-infected. These HIV and HCV transmis-
sion networks within the SHCS underscore the role of
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domestic HCV transmission linked to sexual risk
behavior. Therefore, public health interventions might
reduce HCV transmission even if these are only imple-
mented locally.
COMPARISON WITH OTHER
STUDIES
We believe ours is the ﬁrst published modeling
study to (1) use data on changes in high-risk behavior
to account for changes in HCV incidence among
HIV-infected MSM; (2) evaluate the effects of trends
in high-risk behavior on the course of the HCV epi-
demic, independently of treatment intensiﬁcation; and
(3) incorporate longitudinal data on sexual behavior
and routine HCV screening together with HCV treat-
ment uptake and outcomes. Martin et al.(39) recently
modeled the HCV epidemic among HIV-diagnosed
MSM in the United Kingdom and found that scaling
up DAAs in this setting could substantially reduce
HCV prevalence without behavioral interventions, but
they studied a population with stable primary HCV
incidence, while primary HCV incidence has increased
in the SHCS and in other settings over the last
decade.(3,9) Martin et al. did not include data on the
evolution of high-risk behavior or assess the role of
changing high-risk behavior, independently of treat-
ment intensiﬁcation. Because changes in high-risk
behavior drive the surging HCV epidemic and are a
key target for interventions, we based our predictions
on potential scenarios of high-risk behavior. In con-
trast with the study by Martin et al., our results suggest
that in settings where HCV incidence is rising, scaling
up treatment cannot revert the HCV epidemic if high-
risk behavior continues to spread as it has over the last
decade.
IMPLICATIONS OF FINDINGS
Our model suggests that the most effective strategy
for controlling the HCV epidemic among HIV-
infected MSM is to adopt health promotion interven-
tions that limit high-risk behavior. Targeted interven-
tions to curb the HCV epidemic, such as increasing
access to treatment, are effective if accompanied by
interventions or autonomous saturation that slow the
spread of high-risk behavior. Of note, self-reported
unsafe sex does not reﬂect all high-risk sexual practices
associated with HCV transmission that are not
recorded in the SHCS. Self-reported unsafe sex rather
served as a proxy for high-risk behavior. The good ﬁt
of the model predictions to the incidence data suggests
that self-reported unsafe sex is associated with other
high-risk sexual practices. Trends in self-reported
unsafe sex might therefore predict the future course of
HCV infections and guide interventions to reduce
HCV incidence. The results of this study could be
used to inform public health policy intended to prevent
HCV transmission among HIV-infected MSM.
The validity and scope of our ﬁndings must be deter-
mined in clinical trials or observational studies. These
model projections are based on hypothetical representa-
tive outcomes of interventions to reduce high-risk
behavior (pessimistic, intermediate, optimistic, and
best), but real-world interventions are likely to cluster
around the intermediate scenario. Cost-effectiveness
analyses that consider realistic outcomes of behavioral
interventions are also required to guide implementation
of public health interventions intended to reduce trans-
mission of HCV among HIV-infected MSM.
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